Standardizes and expands upon information available in process patents for "blockbuster" drugs

There is a need to inform the public that generic versions of a drug may not be manufactured by the same process as brand-name drugs and that the different processes may have dramatically different environmental impacts. Two global forces are at odds today?the push for "greener" processes and the push for lower drug prices. This book brings this conflict into sharp focus by discussing in detail the published process chemistry for top-selling small molecule drugs.

Providing insights about process route selection, choice of reagents, and reaction conditions, Pharmaceutical Process Chemistry for Synthesis guides process chemists in identifying best processes for manufacturing these blockbuster drugs as they lose patent protection. Further, it highlights the strategies and methodology that might be useful for expediting the process research and development of the blockbusters of the future. Pharmaceutical Process Chemistry for Synthesis also:

• Presents detailed discussions of the published process chemistry of Lipitor®, Advair Diskus®, Prevacid®, Singulair®, Seroquel®, Effexor XR®, Lexapro®, and Actos®
• Aids in the implementation of green chemistry in pharmaceutical manufacturing by comparing and contrasting known multiple processes to the same target
• Summarizes the known process chemistry by discussing the advantages of one selected route for each drug
• Reflects the range of tasks assigned to process chemists?i.e., manufacturing route selection, conversion of an intermediate to final target
• A multi-level table of contents and comprehensive index of reagents for rapid access to specific information

Written from a refreshingly objective perspective, this book is essential for process chemists who need to devise practical syntheses for increasingly complex drugs in a constantly decreasing time frame.